{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerulonephritis",
    "query": {
      "condition": "Glomerulonephritis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 265,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glomerulonephritis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:51:33.800Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04278729",
      "title": "A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nephrotic Syndrome",
        "Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "Apixaban 5 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 22,
      "start_date": "2021-04-14",
      "completion_date": "2023-09-22",
      "has_results": false,
      "last_update_posted_date": "2023-09-26",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04278729"
    },
    {
      "nct_id": "NCT07182227",
      "title": "PS-002 for the Treatment of IgA Nephropathy in Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A (IgA) Nephropathy"
      ],
      "interventions": [
        {
          "name": "PS-002",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Purespring Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-02",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Baltimore, Maryland • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07182227"
    },
    {
      "nct_id": "NCT05039619",
      "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen/paracetamol",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine hydrochloride (HCl)",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-05-12",
      "completion_date": "2030-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 11,
      "location_summary": "Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039619"
    },
    {
      "nct_id": "NCT00193648",
      "title": "Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone (Avandia)",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab (Humira)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-07",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-10-22",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 2,
      "location_summary": "New Hyde Park, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00193648"
    },
    {
      "nct_id": "NCT01273389",
      "title": "An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "CNTO 136",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-08",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2016-03-24",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273389"
    },
    {
      "nct_id": "NCT00001959",
      "title": "Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrosis",
        "Focal Glomerulosclerosis",
        "Kidney Failure",
        "Nephrotic Syndrome",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "1999-12",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2014-05-26",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001959"
    },
    {
      "nct_id": "NCT06858319",
      "title": "Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Diseases",
        "Kidney Diseases, Chronic",
        "Urological Diseases",
        "Glomerulonephritis",
        "Glomerular Disease",
        "Glomerulonephritis, IGA",
        "Glomerulopathy",
        "Immunoglobulin Disease"
      ],
      "interventions": [
        {
          "name": "zigakibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 220,
      "start_date": "2025-07-28",
      "completion_date": "2031-06-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Orlando, Florida • Clifton Park, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Clifton Park",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Brentwood",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06858319"
    },
    {
      "nct_id": "NCT04572854",
      "title": "Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3G",
        "IC-MPGN",
        "Renal Transplant",
        "Complement 3 Glomerulopathy",
        "Complement 3 Glomerulopathy (C3G)",
        "Dense Deposit Disease (DDD)",
        "Membranoproliferative Glomerulonephritis",
        "Membranoproliferative Glomerulonephritis (MPGN)",
        "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Complement 3 Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-09-07",
      "completion_date": "2026-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04572854"
    },
    {
      "nct_id": "NCT02155803",
      "title": "ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sarcoidosis",
        "Hypercalcemia Due to Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "ACTHAR Gel (adrenocorticotropic hormone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albany Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2015-02",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02155803"
    },
    {
      "nct_id": "NCT00479622",
      "title": "Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "TRU-015",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-08",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2008-05-08",
      "last_synced_at": "2026-05-22T04:51:33.800Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00479622"
    }
  ]
}